NatureMay 6, 2026

A brain reward system reduced by new weight-loss drugs in mice

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Small-molecule GLP1R agonists may suppress reward-driven feeding through central amygdala neurons that reduce dopamine release in the nucleus accumbens.

Evidence

A mechanistic mouse study using humanized GLP1R models found that small-molecule GLP1RAs engage homeostatic circuits and a Glp1r-expressing central amygdala population whose stimulation curtailed hedonic feeding and whose receptor deletion reduced anorectic efficacy for reward-driven intake.

Caveat

The evidence comes from mouse models engineered for human GLP1R selectivity, so implications for substance-use disorder and binge eating remain preclinical.

Simplified

Glucagon-like peptide 1 receptor agonists (GLP1RAs) effectively reduce body weight and improve metabolic outcomes; however, established peptide-based therapies require injections and are complex to manufacture. Small-molecule GLP1RAs promise oral bioavailability and scalable manufacturing, but their selective binding to human versus rodent receptors has limited mechanistic studies. Here we developed humanized GLP1R mouse models to investigate how small-molecule GLP1RAs influence feeding behaviour. We found that these compounds regulate both homeostatic and hedonic feeding through parallel neural circuits. Beyond engaging canonical hypothalamic and hindbrain networks that control metabolic homeostasis, GLP1RAs recruit a discrete population of Glp1r-expressing neurons in the central amygdala, which selectively suppress the consumption of palatable foods by reducing dopamine release in the nucleus accumbens. Stimulating these central amygdalar neurons curtails hedonic feeding, whereas targeted deletion of the receptor in this cell population specifically diminishes the anorectic efficacy of GLP1RAs for reward-driven intake. These findings identify a neural circuit through which small-molecule GLP1RAs modulate reward processing, with implications for the treatment of substance-use disorder and binge eating. 1-3 4-9

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 TherapiesIssue #36

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

↗

A brain reward system reduced by new weight-loss drugs in mice

Abstract

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief